Evidence map›Paper›PMID 38370617›Full record

ArticlebioRxiv : the preprint server for biology2024

Broad de-regulated U2AF1 splicing is prognostic and augments leukemic transformation via protein arginine methyltransferase activation.

Meenakshi Venkatasubramanian, Leya Schwartz, Nandini Ramachandra, Joshua Bennett, Krithika R Subramanian, Xiaoting Chen, Shanisha Gordon-Mitchell, Ariel Fromowitz, Kith Pradhan, David Shechter and 11 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Meenakshi VenkatasubramanianDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Leya SchwartzBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.
Nandini RamachandraBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.
Joshua BennettExperimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Krithika R SubramanianDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Xiaoting ChenDivisions of Human Genetics and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Shanisha Gordon-MitchellBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.
Ariel FromowitzBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.
Kith PradhanBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.
David ShechterBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.
Srabani SahuBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.
Diane HeiserPrelude Therapeutics Incorporated, Wilmington, DE.
Peggy ScherlePrelude Therapeutics Incorporated, Wilmington, DE.
Kashish ChetalDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Aishwarya KulkarniDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Kasiani C MyersDivision of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Matthew T WeirauchDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
H Leighton GrimesExperimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0001-8162-6758
Daniel T StarczynowskiExperimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0002-5771-7462
Amit VermaBlood Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, NY.ORCID 0000-0001-7592-7693
Nathan SalomonisDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0001-9689-2469
Cincinnati Children's Hospital Medical Center · USAlbert Einstein College of Medicine · US

Funding

Training Program in Cancer TherapeuticsT32CA117846 · NCI · UNIVERSITY OF CINCINNATI · PI PRICE, CAROLYN M, TAKIAR, VINITA · 2006 to 2022
$6.5M
Xenotransplant and Genome Editing CoreU54DK126108 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Daniel Starczynowski, YI ZHENG · 2021 to 2026
$5.0M
Decoding innate immune signaling in normal and myelodysplastic hematopoiesisR35HL135787 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI STARCZYNOWSKI, DANIEL · 2017 to 2022
$4.6M
Binding of Epstein Barr Virus EBNA2 Unifies Multiple Sclerosis Genetic MechanismsR01NS099068 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI Leah Claire Kottyan, Matthew Tyson Weirauch · 2017 to 2026
$4.2M
PRMT5-MEP50 Histone Arginine Methylation in Early DevelopmentR01GM108646 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SHECHTER, DAVID · 2014 to 2022
$3.2M
Therapeutic targeting of IRAK4 in MDSR01CA275007 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Daniel Starczynowski, Amit K. Verma · 2022 to 2026
$2.6M
Unbiased identification of spliceosome vulnerabilities across cancerR01CA226802 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI SALOMONIS, NATHAN G. · 2018 to 2022
$2.4M
A rapid spontaneous murine model of CN-AMLR01CA196658 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI GRIMES, H. LEIGHTON · 2016 to 2018
$2.2M
NCI NIH HHS R01 CA196658NCI NIH HHS R01 CA226802NCI NIH HHS R01 CA275007NCI NIH HHS T32 CA117846NHLBI NIH HHS R35 HL135787NIDDK NIH HHS U54 DK126108NIGMS NIH HHS R01 GM108646NINDS NIH HHS R01 NS099068
6 · The paper itself

Abstract

The role of splicing dysregulation in cancer is underscored by splicing factor mutations; however, its impact in the absence of such rare mutations is poorly understood. To reveal complex patient subtypes and putative regulators of pathogenic splicing in Acute Myeloid Leukemia (AML), we developed a new approach called OncoSplice. Among diverse new subtypes, OncoSplice identified a biphasic poor prognosis signature that partially phenocopies

Identifiers

PMID38370617
PMCPMC10871255
OpenAlexW4391656257

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.